OragenicsOGEN
OGEN
About: Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
Employees: 5
0
Funds holding %
of 7,335 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
0.6% less ownership
Funds ownership: 1.87% [Q4 2024] → 1.27% (-0.6%) [Q1 2025]
9% less funds holding
Funds holding: 23 [Q4 2024] → 21 (-2) [Q1 2025]
33% less capital invested
Capital invested by funds: $86K [Q4 2024] → $57.2K (-$28.8K) [Q1 2025]
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Research analyst outlook
We haven’t received any recent analyst ratings for OGEN.
Financial journalist opinion
Neutral
GlobeNewsWire
20 hours ago
Oragenics Q2 2025 Shareholder Update
Advancing Brain-First Recovery Platform Toward Clinical Milestones Pioneering Intranasal Therapeutics for Concussion
Neutral
GlobeNewsWire
3 weeks ago
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an industry leading CDMO with multiple US-based development and manufacturing facilities. Oragenics has partnered with Sterling Pharma Solutions for the GMP production of its lead drug candidate, ONP-002, for the treatment of concussion.
Neutral
GlobeNewsWire
1 month ago
Oragenics Completes Approximately $16.5 Million Offering
Proceeds to drive development of ONP-002, the Company's lead intranasal drug candidate for mild traumatic brain injury Proceeds to drive development of ONP-002, the Company's lead intranasal drug candidate for mild traumatic brain injury
Neutral
GlobeNewsWire
1 month ago
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of up to 800,000 shares of the Company's Series H Convertible Preferred Stock (“Preferred Stock”), no par value, and Warrants to purchase up to an additional 800,000 shares of Preferred Stock of the Company at an exercise price of $25.00 per share (the “Warrants”). The combined public Offering price of each share of Preferred Stock together with an accompanying Warrant is $25.00 (the “Offering”). The Preferred Stock is convertible into the Company's common stock, par value $0.001 per share (the “Common Stock”), at a conversion price of $2.50 per share. The closing of the Offering is expected to occur on or about July 2, 2025, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
2 months ago
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate its Phase II clinical trial evaluating ONP-002, the Company's proprietary neuroprotective therapy, for the treatment of mild traumatic brain injury (mTBI), aka concussion.
Neutral
GlobeNewsWire
3 months ago
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
Webinar to Feature CEO Janet Huffman, Chief Clinical Officer Dr. Frank Peacock, and Dr. James Kelly, Followed by Live Q&A Webinar to Feature CEO Janet Huffman, Chief Clinical Officer Dr. Frank Peacock, and Dr. James Kelly, Followed by Live Q&A
Neutral
GlobeNewsWire
4 months ago
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
SARASOTA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that Chief Medical Officer Dr. James Kelly participated in a panel discussion at the 3rd Nasal Formulation & Delivery Summit, which took place April 1-3, 2025, in Boston, MA.
Neutral
GlobeNewsWire
4 months ago
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry Momentum ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry Momentum
Neutral
GlobeNewsWire
4 months ago
Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K
SARASOTA, Fla., March 18, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission on March 14, 2025.
Neutral
GlobeNewsWire
5 months ago
Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
SARASOTA, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced the submission of its Investigator's Brochure (IB) application in preparation for its Phase II clinical trial using ONP-002 in Australia. This milestone represents an important step in advancing ONP-002, a novel intranasal neurosteroid, as a potential treatment for mild traumatic brain injury (mTBI), commonly known as concussion.
Charts implemented using Lightweight Charts™